Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...

The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...

Folks with peanut allergies don't have to worry that someone might be munching on the nuts during an airline flight, ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...